Cited by 723Cancer Immunotherapy and BiomarkersChemokine receptors and signalingT-cell and B-cell Immunology

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

Open access

Chow, Melvyn T., Ozga, Aleksandra J., Servis, Rachel L., Frederick, Dennie T., Lo, Jennifer A., Fisher, David E., Freeman, Gordon J., Boland, Genevieve M., Luster, Andrew D.·2019·Immunity

DOI 10.1016/j.immuni.2019.04.010PMC PMC6527362

Open this paper in CoChat — free account Open PDF

Abstract

Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors. We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded poorly to anti-PD-1 treatment. CXCR3 and its ligand CXCL9 were critical for a productive CD8+ T cell response in tumor-bearing mice treated with anti-PD-1 but were not required for the infiltration of CD8+ T cells into tumors. The anti-PD-1-induced anti-tumor response was facilitated by CXCL9 production from intratumoral CD103+ dendritic cells, suggesting that CXCR3 facilitates dendritic cell-T cell interactions within the tumor microenvironment. CXCR3 ligands in murine tumors and in plasma of melanoma patients were an indicator of clinical response to anti-PD-1, and their induction in non-responsive murine tumors promoted responsiveness to anti-PD-1. Our data suggest that the CXCR3 chemokine system is a biomarker for sensitivity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could improve clinical outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2019.04.010

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“A Functional CD8 T Cell Response after PD-1 Blockade Is Dependent on CXCR3 Given the reported role of CXCR3 in T cell recruitment into tumors and the importance of pre-existing intratumoral CD8 T cells for effective PD-1 blockade therapy (Tumeh et al., 2014), we hypothesized that the reduced therapeutic effect of anti…”
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 2×
“In fact, other chemokine systems, such as CCR2, CCR5, CX3CR1, are associated with T cell migration into tumors (Ahrends et al., 2017; Berghuis et al., 2011; Chew et al., 2012; Fridman et al., 2012; González-Martı́n et al., 2011; Harlin et al., 2009; Liu et al., 2015; Mlecnik et al., 2010).”
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M. J., Obenauf, A. C., Angell, H. K., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,455 · cited 1×
“Correlative human studies have highlighted the potential importance of chemokines for T cell infiltration into tumors and for patient survival (Bindea et al., 2013; Messina et al., 2012).”
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581 · cited 1×
“To this end, we used fingolimod (FTY720) (a functional antagonist of the S1P1 receptor) to block the egress of T cells from the lymphoid organs (Matloubian et al., 2004) one day before the initiation of anti-PD-1 therapy (Figure 2A).”
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“Although CD8 T cells are considered the primary target of anti-PD-1, anti-PD-1 can directly affect macrophages as well (Gordon et al., 2017).”
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,119 · cited 1×
“CXCR3 on CD8 T Cells Is Essential for Anti-PD-1Mediated CD8 T Cell Activation CXCR3 is expressed not only on T cells but also on other hematopoietic cells, such as innate lymphocytes and plasmacytoid DCs (Griffith et al., 2014).”
Self-citation
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070 · cited 2×
“Previous studies demonstrated that terminally exhausted CD8+ T cells upregulate their expression of granzyme B (Im et al., 2016; Utzschneider et al., 2016).”
Self-citation

Show all 57 references

Sorted by citations

Items 401–500 of 723

Archetypes of checkpoint-responsive immunity
Im, K. W., Combes, A. J., Spitzer, M. H., Satpathy, A. T., & Krummel, M. F. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.007 · Cited by 13
“Noteworthy, in one recent study, TMB was associated with ICB responsiveness in mouse MC38 colorectal carcinoma tumor models; the second most correlated gene signature was intratumoral DC-derived Cxcl9 (encoding CXCL9) – a chemokine described in mice as being produced by intratumoral cDC1s that functions to attract CD8…”
Background
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
Carbone, M. L., Madonna, G., Capone, A., Bove, M., Mastroeni, S., Levati, L., Capone, M., Ascierto, P. A., Galitiis, F. D., D’Atri, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09373-9 · Cited by 11
Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker
Berszin, M., Michaelides, I., Siemert, J., Röhl, L., Wellhausen, J., Wald, T., Bohr, C., Künzel, J., Gradistanac, T., Dietz, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.795277 · Cited by 9
“Although the introduction of monoclonal antibodies against PD-1 such as pembrolizumab has revolutionized the therapy against many cancer forms, including HNSCC (8), and it is now being used as a first-line agent against R/MHNSCC after positive results from the KEYNOTE-048 study (11), only a fraction of patients show l…”
Background
Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapyPreprint
Gu, K., Liang, T., Hu, L., Zhao, Y., Ying, W., Zhang, M., Chen, Y., Liang, B., Lin, X., Zhang, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.30.605730 · Cited by 11
“Multiple studies have highlighted that IFN-γ -induced chemokines, such as CXCL10 and CXCL11, play a crucial role in eliciting chemotaxis 47-49 , especially of monocytes/macrophages and T cells within the TME.”
Background
New insights into combined immunotherapy for hepatocellular carcinoma associated with liver cirrhosis
Liu, Y., Cong, K., Li, Q., Zhang, D., & Sheng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1741398 · Cited by 12
The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer
Yilmaz, A., Haerri, L., Granda, M. E., Coquoz, O., Lan, Q., & Rüegg, C. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00903-6 · Cited by 10
Mechanistic insights into the interactions between cancer drivers and the tumour immune microenvironment
Mišetić, H., Keddar, M. R., Jeannon, J., & Ciccarelli, F. D. (2023) · Genome Medicine · doi:10.1186/s13073-023-01197-0 · Cited by 10
“In a similar way, we tested other described predictors of response to ICB, namely T-cell-inflamed gene-expression profile (GEP) [61], PDL1 [62], CD8A [63] and CXCL9 [64] expression levels, gender [65] and age at diagnosis [66].”
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
Kaistha, B. P., Kar, G., Dannhorn, A., Watkins, A., Opoku‐Ansah, G., Ilieva, K. M., Mullins, S., Anderton, J., Galvani, E., Garçon, F., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2296048 · Cited by 10
“28 Elevated expression of PDCD1 (PD-1) infer tumoral T-cells in those CT26 tumor bearing mice are likely activated and/or exhausted and strongly support the inclusion of aPD-L1 to counteract adaptive immune-resistance to anti-tumor effects.”
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells
Kline, K. A. F., Luetkens, T., Koka, R. M., Kallen, M. E., Chen, W., Ahmad, H., Omili, D. O., Iraguha, T., Gebru, E., Fan, X., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03619-9 · Cited by 10
“In addition to its potential role in orchestrating CNS-directed T cell migration, this chemokine and CXCR3 have also been shown to be involved in sensitivity to immune checkpoint inhibition and regulating T cell responses in general [21, 22].”
Background
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Campbell, M. J., Wolf, D. M., Yau, C. S. F., Swigart, L. B., Wulfkuhle, J., Gallagher, R. I., Zhu, Z., Bolen, J., VandenBerg, S. R., Hoyt, C. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101799 · Cited by 10
Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response
Gorría, T., Sierra-Boada, M., Rojas, M., Figueras, C., Marín, S., Madurga, S., Cascante, M., & Maurel, J. (2025) · Cancers · doi:10.3390/cancers17030498 · Cited by 10
“…hubs in the stromal zone, at the tumor–luminal interface of myeloid cells (macrophages, DCs, and granulocytes) and CXCR3-ligand+ effector T cells [71,72] Therefore, the spatial localization of these cell groups is not random: they are strategically placed to coordinate with T cells to interact…”
CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects
Zheng, D., Qin, L., Lv, J., Che, M., He, B., Zheng, Y., Lin, S., Qi, Y., Li, M., Tang, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102020 · Cited by 11
Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy
Sax, A., May, P., Enßle, S., Soliman, N., Nedelko, T., Mandracci, G., Stögbauer, F., Joachim, L., Winter, C., Bassermann, F. C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010433 · Cited by 11
Oxidized Low-Density Lipoprotein as a Potential Target for Enhancing Immune Checkpoint Inhibitor Therapy in Microsatellite-Stable Colorectal Cancer
Zhang, X., Ye, X., & Jin, H. (2025) · Antioxidants · doi:10.3390/antiox14060726 · Cited by 14
“This cellular architecture demonstrates spatially organized precision—myeloid cells are strategically positioned to synergize with T cells, thereby optimizing tumor-cell interaction efficiency [130,131].”
Resident Memory T Cells in the Tumor Microenvironment
Williams, J. B., & Kupper, T. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_3 · Cited by 11
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
Al‐Shaebi, F., Safi, M., Algabri, Y. A., Al‐Azab, M., Al-Danakh, A., Alradhi, M., Reem, A., & Zhang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099696 · Cited by 9
“By interacting with its receptor Cxcr3, Cxcl9 has been demonstrated to enhance the activity of T cell killers considerably (62), which may explain why PD-1 inhibition was more effective against IL-34 HM-1 tumors.”
Background
Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
Lin, A., Xu, W., Luo, P., & Zhang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721181 · Cited by 10
“For example, CXCR3 can be used as an important biomarker for predicting the effect of treatment with anti-PD-1 in melanoma patients (Chow et al., 2019).”
Background
Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia
Yan, Y., Upadhyaya, R., Zhang, V. W., & Berg, T. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.003 · Cited by 11
The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development
Fasoulakis, Z. N., Koutras, A., Ntounis, T., Pergialiotis, V., Chionis, A., Katrachouras, A., Palios, V.-C., Symeonidis, P., Valsamaki, A., Syllaios, A., et al. (2022) · Cancers · doi:10.3390/cancers14071649 · Cited by 10
Activating the CXCR3/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinomaPreprint
Shinn, C. K., Saddawi‐Konefka, R., Salanga, C. L., Schokrpur, S., Gutkind, J. S., & Handel, T. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650529 · Cited by 10
“…amplification of CXCR3 signaling within the TME leads to improved responses to ICB in models of colorectal carcinoma, melanoma, and non-small cell lung cancer (27, 131) . mRNA-based therapeutics are also emerging as a platform for the intratumoral delivery of other immunomodulatory proteins (132) .”
Influential
A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies
Guo, J., Niu, Z., Lv, R., Yuan, J., Zhang, Z., Guan, X., Li, D., Zhang, H., Zhao, A., Feng, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111782 · Cited by 9
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer
Zuo, X., Cheng, Q., Wang, Z., Liu, J., Lu, W., Wu, G., Zhu, S., Liu, X., Lv, T., & Song, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112478 · Cited by 9
Molecular Susceptibility and Treatment Challenges in Melanoma
Shenoy, P. V., Nag, R., Kolathur, K. K., Malik, Y., Varanasi, S. M., Angom, R. S., & Mukhopadhyay, D. (2024) · Cells · doi:10.3390/cells13161383 · Cited by 12
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy
Murata, D., Azuma, K., Murotani, K., Kawahara, A., Nishii, Y., Tokito, T., Sasada, T., & Hoshino, T. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03781-8 · Cited by 9
“In the cancer immune cycle, CXCL10 promotes T-cell trafficking to tumors, whereas it does not promote T-cell infiltration associated with CD8+ TIL density [1, 32].”
Background
Correlation between PDGF-BB and M1-type macrophage in inflammatory bowel disease: a case-control study
Fang, Z., Qu, S., Ji, X., Zheng, C., Mo, J., Xu, J., Zhang, J., & Shen, H. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03518-y · Cited by 10
Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance
Mei, T., Ye, T., Huang, D., Xie, Y., Xue, Y., Zhou, D., Wang, W., & Chen, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01009-6 · Cited by 10
Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma
Liu, X., Jiang, R., Xu, Y., Xu, X., Fang, L., Gao, G., Han, L., Chen, Y., Du, H., Cai, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114725 · Cited by 9
Immune Niches in Cancer
Slingerland, N., Runderkamp, E., & Thommen, D. S. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082724-123843 · Cited by 10
Significance of immunogenic cell death-related genes in prognosis prediction and immune microenvironment landscape of patients with cutaneous melanoma
Fu, W., & Ma, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988821 · Cited by 9
“Chemokine receptor CXCR3 has been reported to be a biomarker of sensitivity to PD-1 blockade (Chow et al., 2019; Telli et al., 2021).”
Background
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Ye, D., Desai, J., Shi, J., Liu, S. M., Shen, W., Liu, T., Shi, Y., Wang, D., Liang, L., Yang, S., et al. (2023) · Biomarker Research · doi:10.1186/s40364-023-00465-w · Cited by 9
Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients
Shen, H.-Y., Xu, J.-L., Zhu, Z., Xu, H.-P., Liang, M., Xu, D., Chen, W., Tang, J., Zheng, F., & Zhang, J. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100942 · Cited by 9
“…lymphocytes; TAA, tumor-associated antigen; TSA, tumor-specific antigen; HLA, human leukocyte antigen; APM, antigen processing and presentation machinery; pAPCs, professional antigen presenting cells; DCs, dendritic cells; ssGSEA, single-sample gene set enrichment analysis; OS, overall…”
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma
Hornsteiner, F., Vierthaler, J., Strandt, H., Resag, A., Fu, Z., Außerhofer, M., Tripp, C. H., Dieckmann, S. M., Kanduth, M., Farrand, K. J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008606 · Cited by 10
“For example, Xcl1 and Ccl5 mediate cDC1 infiltration into tumors, 47 whereas Cxcl9 and Cxcl10 are important for DC-T cell interaction by recruitment of CXCR3 + effector T cells 48 49 and for effective T cell-mediated melanoma growth control.”
Background
Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events
Ashoori, M. D., Suzuki, K., Tokumaru, Y., Ikuta, N., Tajima, M., Honjo, T., & Ohta, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618711 · Cited by 9
“These chemokines are responsible for CD8 T cell recruitment in various inflammation models (30– 32) and in tumors (41, 42).”
Background
Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy
Lin, X., Wang, X., Gu, Q., Lei, D., Liu, X., & Yao, C. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe7b3 · Cited by 8
Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Rijnders, M., Balcioglu, H. E., Robbrecht, D. G. J., Oostvogels, A. A. M., Wijers, R., Aarts, M. J. B., Hamberg, P., van Leenders, G. J. L. H., Nakauma-González, J. A., Voortman, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3319 · Cited by 9
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 9
“cDC1s also express CXC-chemokine ligand 9(CXCL9) and CXCL10 to activate CXCR3+ T and NK cells, recruit CD8+ T cells into the tumor sites, and foster the efficacy of anti-PD1 or anti-TIM-3 therapy (de Mingo Pulido et al., 2018; Chow et al., 2019).”
Background
Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells
Yabuki, Y., Mitsuhashi, A., Ogino, H., Yoshida, A., Nguyen, N. T., Yoneda, H., Ozaki, R., Tsukazaki, Y., Morita, Y., Nokihara, H., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35301 · Cited by 8
“20,21 In addition, our previous study indicated that tumor-derived IFN-inducible CXCL10/11 suppressed tumor angiogenesis following treatment with PD-1/PD-L1 antibody.”
IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
Ohno, Y., Okamura, H., Yagita∥, H., & Tanaka, T. T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1533808 · Cited by 8
Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy
Wang, Y.-Y., Lin, J., Wu, W.-W., Fu, Z., Cao, F., Chen, Y., Mo, H., Hui, S., Liu, Z., Zeng, Z.-L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59193-4 · Cited by 12
The metastatic role of the CXCL10-CXCR3 axis and its therapeutic potential in osteosarcoma
Gyau, B. B., Wang, J., Chen, X., Clement, M. A., Man, Z. D., Major, A. M., Weiser, M. C., Xu, J., Hicks, J., & Man, T. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100690 · Cited by 8
“…no difference in the absolute numbers of effector CD8 + T lymphocytes between CXCR3 -/- melanoma mice and controls, suggesting that CXCR3 primarily influences T cell positioning with CXCL10-expressing dendritic, macrophage, or Th1 cells, rather than controlling intratumoral infiltration [20,52].”
An Epigenetic Nanoagonist Facilitates T Cell Priming, Recruitment, and Reinvigoration in Tumors Resistant to PD‐L1 Therapy
Zhao, X., Qin, X., Wang, R., Wang, Y., He, Y., Wang, Y., Li, K., Zhang, P., Yang, C., Wang, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202502800 · Cited by 9
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment
van Dam, S., Krijgsman, D., Küçükköse, E., Verdonschot, M. E. L., Amini, M., Blokx, W. A. M., van Eijs, M. J. M., Verheijden, R. J., Kranenburg, O., Suijkerbuijk, K. P. M., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03137-8 · Cited by 9
Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment
Kwok, T., Silva, I., Korpe, S., Dong, H., & Lancaster, J. N. (2025) · iScience · doi:10.1016/j.isci.2025.113538 · Cited by 10
“25 26–29 Taken together, these findings support TAM repolarization during ICB.”
CXCL10 and CCL5 as feasible Biomarkers for Immunotherapy of Homologous Recombination Deficient Ovarian Cancer
Li, Y., & Han, Y. (2022) · PubMed Central · doi:10.5281/zenodo.6997707 · Cited by 8
Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design
Lu, Y., & You, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114457 · Cited by 8
Dendritic cell maturation in the tumor microenvironment
Miao, Y., Liu, Y., Tang, H., & Zhang, Z. (2023) · National Science Open · doi:10.1360/nso/20220053 · Cited by 9
“In addition, CXCL9 produced by CD103 + DCs is required for the anti-PD-1 responses by regulating the interaction between CD8 + T cells and DCs [153].”
Background
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis
Suzuki, T., Matsuura, K., Suzuki, Y., Okumura, F., Nagura, Y., Sobue, S., Matoya, S., Miyaki, T., Kimura, Y., Kusakabe, A., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6876 · Cited by 7
“16 Albeit without significance, serum CXCL10 levels were numerically higher at baseline and at the start of the second course and more strongly increased from baseline to the start of the second course among responders than among non-responders in the initial therapeutic response assessment of…”
Background
Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors
Wan, W., Han, W., Chen, J., Li, Y., Zhao, L., Gao, M., Shen, C., Liu, N., Deng, W., Ma, S., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401161 · Cited by 8
TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in mice
Fay, M., Sievers, C. M., Robbins, Y. L., Yang, X., Huynh, A. P., Redman, J. M., Hodge, J. W., Schlom, J., Gulley, J. L., Allen, C. T., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110520 · Cited by 8
“Given the important roles of CXCR3 in T cell trafﬁcking and function, 25–27 we next assessed whether our pre-clinical observation of increased T cell CXCR3 expression after a TGF-b + a PDL1 treatment could be made in archived PBMC from patients with newly diagnosed HNSCC treated with a TGF-b + a…”
Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids
Lo, C., Chiu, T., Liu, Y., Huang, L., Yeh, T., Huang, K., Liu, K.-L., Hsu, C., Fang, M., Huang, Y., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071316 · Cited by 8
“The CXCL9–CXCR3 axis was correlated with improved PD-1 immunotherapy outcome [32].”
Background
New Clones on the Block
Acharya, N., & Anderson, A. C. (2019) · Immunity · doi:10.1016/j.immuni.2019.09.018 · Cited by 9
Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas
Su, C., Kent, C. L., Pierpoint, M., Floyd, W., Luo, L., Williams, N. T., Ma, Y., Peng, B., Lazarides, A. L., Subramanian, A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.178767 · Cited by 8
Subverting Attachment to Prevent Attacking: Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion
Mastrogiovanni, M., Donnadieu, E., Pathak, R., & Bartolo, V. D. (2024) · Biology · doi:10.3390/biology13110860 · Cited by 8
“Conversely, CXCL9 and CXCL10 produced by DCs have been shown to increase the contact with CXCR3+ CTLs, thereby enhancing the e ﬃ - cacy of programmed cell death protein 1 (PD-1) blockade therapy [16,17].”
Influential
Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy
Kang, Y., Choi, D., Moon, D., Lee, K.-J., Oh, Y., Yang, J.-H., Jeong, S., Park, U., Im, S., Yang, S. H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1477171 · Cited by 7
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma
Placke, J., Bottek, J., Váraljai, R., Shannan, B., Scharfenberg, S., Krisp, C., Spangenberg, P., Soun, C., Siemes, D., Borgards, L., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae433 · Cited by 7
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma
Yonemoto, T., Ogasawara, S., Kanogawa, N., Miwa, C., Fujiya, M., Tsuchiya, T., Sawada, M., Akatsuka, T., Izai, R., Yumita, S., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14160 · Cited by 7
“30–33 Although our data did not reflect it, transientelevationsininflammatorycytokines,suchasIL - 6andTNF -α , have also been reported, signaling systemic immune activation.”
Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy
Enßle, S., Sax, A., May, P., Khawanky, N. E., Soliman, N., Perl, M., Enssle, J. C., Krey, K., Ruland, J., Pichlmair, A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2504244 · Cited by 7
“50 Taken together, these data suggest that tumor cell-released inducible (rather than constitutive) DAMPs, including pro-inflammatory cytokines and chemokines, may contribute to the immunogenicity of RIG-I/caspse-3/GSDME-driven pyroptotic tumor cell death.”
Tumor vasculature–mediated formation of tertiary lymphoid structures: unraveling spatiotemporal coupling to optimize vasculo-immunotherapy
Lei, L., Long, J., Chen, C., Zheng, B., Lin, X., Fang, P., Chen, M., Jiang, X., Wang, Y., & Wang, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117574 · Cited by 8
Chemokine–chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming
Zhao, Y., Wang, X., Lei, T. B., Lu, H., Zhao, Y., & Wang, G. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004009 · Cited by 7
“[161,162] CXCR3 also mediates distinct downstream signaling pathways depending on the ligand.”
Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma
Romano, G., Paradiso, F., Li, P., Shukla, P., Barger, L. N., Naggar, O. S. E., Miller, J. P., Liang, R. J., Helms, T. L., Lazar, A. J., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0224 · Cited by 7
CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma
Lindner, A. K., Martowicz, A., Untergasser, G., Haybaeck, J., Compérat, É., Kocher, F., Seeber, A., Thurnher, M., & Pichler, R. (2023) · Cancers · doi:10.3390/cancers15041001 · Cited by 7
“CXCR3 ligands additionally were an indicator of clinical response to anti PD-1 in patient plasma, indicating that the CXCR3 chemokine is a biomarker for efficacy to PD-1 blockade [50].”
BackgroundInfluential
Histological Type, Cytotoxic T Cells and Macrophages in the Tumor Microenvironment Affect the PD-L1 Status of Gastric Cancer
Ivanović, T., Božić, D., Benzon, B., Čapkun, V., Vukojević, K., & Durdov, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11030709 · Cited by 7
“In a mouse model, TME-resident memory cells significantly enhance antitumor capacity and secrete interferon-γ (IFN-γ) to inhibit tumor progression [12].”
Background
Ionizing Radiation Selectively Increases CXC Ligand 10 Level via the DNA-Damage-Induced p38 MAPK-STAT1 Pathway in Murine J774A.1 Macrophages
Seo, Y. N., Baik, J. S., Lee, S. M., Lee, J. E., Ahn, H. R., Lim, M. S., Park, M., & Kim, S. (2023) · Cells · doi:10.3390/cells12071009 · Cited by 7
“Irradiation increased CXCL10 production in MC38 mouse colon adenocarcinoma cells [37].”
Background
The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
Seitz, S., Dreyer, T. F., Stange, C., Steiger, K., Wohlleber, D., Anton, M., Pham, T. A., Sauter-Peschke, D., Reuning, U., Multhoff, G., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101130 · Cited by 7
Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity
Gorline, L., Carmo, F. L. R. D., Bourdely, P., Bornères, J., Vaudiau, N., Semervil, A., Vétillard, M., Coulibaly, A. S. K., Jugniot, N., Ok, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-68018-3 · Cited by 6
Miniature and versatile genome regulation TnpB-ωRNA toolkits facilitate cancer immunotherapy
Lu, J., Lai, J., Cheng, L., Zhan, H., Jie, K., Liu, C., Huang, L., Cen, M., Liu, S., Chen, Z., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71327-w · Cited by 6
30-color full spectrum flow cytometry panel for deep immunophenotyping of T cell subsets in murine tumor tissue
Liu, Y., Xu, X., Liu, D., Wu, X., Gao, Y., Wang, H., Yan, F., Yang, W., Zhao, D., He, F., et al. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113459 · Cited by 6
Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma
Figueiredo, A. B., Silva, M. J. B. E., Evangelista, G. F. D. B., Galdino, N. A. D. L., Kuil, L. D. M., Santos, I. P., Morais, K. L. P., Cavalcanti, C. M., Moredo, L. F., Neto, J. P. D., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32624 · Cited by 6
“( For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) have higher concentrations of CXCL9 during treatment, but not at baseline [14].”
Background
PLCε1 suppresses tumor growth by regulating murine T cell mobilization
Strazza, M., Adam, K. R., Smrcka, A. V., Lerrer, S., & Mor, A. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13409 · Cited by 6
Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
Kang, S.-W., Rainczuk, A., Oehler, M. K., Jobling, T. W., Plebanski, M., & Stephens, A. N. (2021) · Diagnostics · doi:10.3390/diagnostics11061048 · Cited by 6
“Expression of CXCR3 on tumour-infiltrating CD8+ T effector cells also potentiates immune checkpoint inhibition by anti-programmed cell death-1 (PD-L1) in a colorectal cancer model [8].”
Background
Spatiotemporal and cell-state control of antigen presentation during tolerance and immunity
Hor, J. L., & Germain, R. N. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102357 · Cited by 6
Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
Hao, X., Falo, L. D., Chen, G., Zhang, J., Carey, C. D., Storkus, W. J., Falo, L. D., & You, Z. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001179 · Cited by 6
Expression profile and prognostic value of CXCR family members in head and neck squamous cell carcinoma
Shen, Y., Zhou, C., Cao, Y., Li, Q., Deng, H., Gu, S., Wu, Y., & Shen, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02713-z · Cited by 6
Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Takada, H., Yamashita, K., Osawa, L., Komiyama, Y., Nakakuki, N., Muraoka, M., Suzuki, Y., Sato, M., Kobayashi, S., Yoshida, T., et al. (2023) · Oncology · doi:10.1159/000531689 · Cited by 6
Integrated single-cell and spatial analysis identifies context-dependent myeloid-T cell interactions in head and neck cancer immune checkpoint blockade responsePreprint
Golfinos, A. E., Ložar, T., Khatri, P., Hu, R., Harari, P. M., Lambert, P. F., Fitzpatrick, M. B., & Dinh, H. Q. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.24.644582 · Cited by 6
MYO1F in neutrophils is required for the response to immune checkpoint blockade therapy
Qu, Y., Liang, W., Yu, M., Wang, C., Luo, M., Zhong, L., Li, Z., & Wang, F. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241957 · Cited by 5
Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS
Griffiths, E. A., Srivastava, P., Gomez, E. C., Matsuzaki, J., Odunsi, K. O., Dillon, L. W., Mukherjee, D., Hourigan, C. S., Peng, J. J., Bandyopadhyay, S., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100106 · Cited by 5
“46,47 A decrease in cDC1 number or function associated with MDS could explain why patients 3DVN and 4DVN, who had undetectable and high numbers cDC1s respectively, both showed no induction of CD8 + T cells.”
Comparing DC subsets in solid tumors: what about DC3s?
Pachocki, C. J., Boes, M. L., & Affandi, A. J. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf021 · Cited by 5
“In tumor tissues, CD103 + cDC1s express CXCL9 and CXCL10 that attract activated T and NK cells through CXCR3 [54].”
FLNB overexpression promotes tumor progression and associates with immune suppression, evasion and stemness in pancreatic cancer
Fan, G. (2024) · American Journal of Cancer Research · doi:10.62347/nuxc8231 · Cited by 6
Lymphatic chain gradients regulate the magnitude and heterogeneity of T cell responses to vaccination
Conlon, M. T., Huang, J. Y., & Gerner, M. Y. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241311 · Cited by 6
Impact of multiple hits with cognate antigen on memory CD8+ T-cell fate
Takamura, S. (2020) · International Immunology · doi:10.1093/intimm/dxaa039 · Cited by 5
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
Sharon, S., Baird, J. R., Bambina, S., Kramer, G. F., Blair, T. C., Jensen, S. M., Leidner, R. S., Bell, R. B., Casap, N., Crittenden, M. R., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27982 · Cited by 5
“74 days, respectively), consistent with data showing that preexisting immune responses in tumors are essential to the success of checkpoint inhibitors [20, 21].”
Background
Pt–Te–Nanorod-Based Photothermal Chemokine Immunotherapy for All Stages of Cancer via Adaptive and Innate Immunity
Kang, S., Gil, Y., Chae, S.-Y., Jang, H., & Min, D. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c06048 · Cited by 5
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge
Martínez-Vila, C., González‐Navarro, E. A., Teixidó, C., Martin, R., Aya, F., Juan, M., & Arance, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179506 · Cited by 5
“Also, in another scientific study that analyzed plasma samples from 28 patients with advanced melanoma who were treated with pembrolizumab and nivolumab plus ipilimumab, responders ( n = 18) had a greater quantity of CXCL9 and CXCL10 compared to non-responders ( n = 10) [100].”
Background
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines
Sobral, M. C., Cabizzosu, L., Kang, S. J., Ruark, K. T., Najibi, A. J., Lane, R. S., Vitner, E. B., Ijaz, H., Dellacherie, M. O., Dacus, M. T., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322356121 · Cited by 5
“…lymph nodes) can prime naive tumor - antigen - specific T cells; those in tumors can attract the progeny of previously activated T cells ( 21 , 22 ), provide them with survival signals ( 23 ), and enable their effector antitumor functions ( 20 , 24 ). cDCs also engage in productive…”
CXCR3: Here to stay to enhance cancer immunotherapy?
Rogava, M., & Izar, B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.044 · Cited by 5
“[9] Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, et al.”
Background
Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma
Li, C., Tian, C., Liu, Y., Liang, J., Zeng, Y., Yang, Q., Liu, Y., Wu, D., Wu, J., Wang, J., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.619821 · Cited by 5
Identification of Novel Tumor Microenvironment Regulating Factor That Facilitates Tumor Immune Infiltration in Cervical Cancer
Xu, J., Huang, Z., Wang, Y., Xiang, Z., & Xiong, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.846786 · Cited by 5
“This may be due to the antitumor response of CXCR3-signaling CD8 T cells in the tumor microenvironment, which leads to a better prognosis of patients (23).”
Background
Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets
Bujanda, Z. A. L., Hadavi, S. H., de Porras, V. R., Martinez‐Balibrea, E., & Dallos, M. C. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.008 · Cited by 5
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5Preprint
Dawson, J. R. D., Wadman, G. M., Zhang, P., Tebben, A. J., Carter, P. H., Gu, S., Shroka, T. M., Roman, L. B., Salanga, C. L., Handel, T. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.15.567150 · Cited by 7
Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22Preprint
Maru, S. Y., Wetzel, M., Mitchell, J. T., Groß, N., Andaloori, L., Howe, K., Kartalia, E., Mo, G., Leatherman, J. M., Ho, W. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645833 · Cited by 4
Microwave ablation combined with α-PD-L1 enhances abscopal effect and promotes CTL activation and intratumoral homing by a cytokine network involving IFN-γ and CXCL9
Ma, F., Miao, X., Lin, Y., Luo, X., Chen, T., Ni, Z., & Wang, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114498 · Cited by 4
Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer
Qi, Y., Ge, H., Sun, X., Wei, Y., Zhai, J., Qian, H., Mo, H., & Ma, F. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103423 · Cited by 4
Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9
Jacobson, O., Zhang, H. H., Olkowski, C. P., Ghaemi, B., Basuli, F., Shi, J., Bell, M. M., Parween, F., Ganesan, S., Esparza, T. J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269795 · Cited by 4
“Like other chemokines, CXCL9 binds to glycosaminoglycans ( 9 , 10 ), which are found on cell surfaces and in the extracellular matrix, and recruits and positions cells expressing its receptor, C-X-C motif chemokine receptor 3 (CXCR3), in the tumor microenvironment (TME) ( 11 ).”
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update
Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5
Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer
Lam, C., Lanchoney, O., Maddipatla, V., Markosyan, N., Joshi, N., Hu, X., Ray-Fofana, C., Zeng, S., DeMatteo, R. P., Vonderheide, R. H., et al. (2026) · npj Breast Cancer · doi:10.1038/s41523-025-00889-7 · Cited by 4
“Prior studies have demonstrated that the intratumoral activity of CXCR3 and its ligand CXCL9 are required for anti-PD-1 ef ﬁ cacy 47 .”
CAR-T/NK/M-based combination therapies in cancer: A comprehensive review
Vaja, S., Khandelwal, S., Vora, C., Khan, A. A., Wajeed, S., Sk, M. H., & Baig, M. S. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101269 · Cited by 4
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer
Shen, C., Liu, C., Hu, D., Ge, H., Cheng, L., Qin, R., Zhao, X., Wang, Y., & Niu, H. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013809 · Cited by 4
Exercise and CD8+ T cells: mechanisms of immune modulation in antitumor responses
Liu, L., Deng, Z., Fang, R., Zou, M., Ren, J., Gao, Y., Peng, J., & Hao, L. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02659-9 · Cited by 4
The dual role of the CXCL9/10/11-CXCR3 axis in the tumor immune microenvironment: Mechanisms, therapeutic implications, and clinical translation
Liu, J., Yin, T., Wu, Y., Peng, X., Zhang, J., & Zhan, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108254 · Cited by 5

Authors: Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D.
Affiliations: Harvard University (US)
Corresponding author: Luster, Andrew D.
ORCID: Ozga, Aleksandra J.
Frederick, Dennie T.
Lo, Jennifer A.
Fisher, David E.
Freeman, Gordon J.
Boland, Genevieve M.
Luster, Andrew D.
Venue: Immunity
Publisher: Elsevier BV
Published: 2019-06
Volume: 50
Issue: 6
Pages: 1498-1512.e5
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2019.04.010
PMC: PMC6527362
OpenAlex: W2945224722
Cited by: 716
References: 57
Citations by year: 2026: 83 · 2025: 98 · 2024: 120 · 2023: 128 · 2022: 96 · 2021: 90 · 2020: 81 · 2019: 19
FWCI: 30.30
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 384 d)
Locations: Immunity (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (AR043369)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
National Institutes of Health (AR043369, CA204028, AI112521, CA222871, CA163222)
Melanoma Research Alliance
Cancer Research Institute
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CXCR3, CXCL9, anti-PD-1 therapy, chemokine system, CD8+ T cells, CD103+ dendritic cells, dendritic cell-T cell interaction, tumor microenvironment, melanoma, predictive biomarkers, immunotherapy resistance
MeSH terms: Antineoplastic Agents, Immunological, Animals, Disease Models, Animal, Humans, Lymphocyte Activation, Neoplasms, Biomarkers, T-Lymphocyte Subsets, Mice, Knockout, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Receptors, CXCR3, Immunomodulation, Molecular Targeted Therapy, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks